Skip to content

High-fat Yogurt and Plasma Lipids Profile

Comparison of the Impact of Saturated Fat From High-fat Yogurt or Low-fat Yogurt and Butter on Cardiometabolic Risk Markers: a Randomized Cross-over Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05589350
Enrollment
30
Registered
2022-10-21
Start date
2022-10-15
Completion date
2023-04-13
Last updated
2023-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasma Lipid Profile

Brief summary

The goal of this clinical trial is to compare the effect of saturated fat intake from different source on cardiometabolic risk markers in healthy subjects. The main question it aims to answer are: -Does intake of saturated fat in the form of high-fat yogurt have a different effect on cardiometabolic risk factors than intake of the same amount from butter? In this study, in two periods of 4 weeks, the effect of receiving saturated fat from high-fat yogurt compared to receiving the same amount of saturated fat from butter and low-fat yogurt on the plasma concentration of lipids, cholesterol, insulin, and some inflammatory factors will be studied in healthy subjects.

Interventions

OTHERsaturated fat intake

Intake of saturated fat from yogurt and animal butter daily for 4-week period

Sponsors

Shahid Beheshti University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy people who do not use lipid-lowering, blood pressure control or diabetes medications

Exclusion criteria

* Taking supplements of omega-3 fatty acids, or antioxidants

Design outcomes

Primary

MeasureTime frameDescription
Plasma lipid profile4 weeksPlasma concentrations of cholesterol, high-density lipoprotein cholesterol, Low-density lipoprotein cholesterol, and triglyceride

Secondary

MeasureTime frameDescription
Glycemic measures4 weeksFasting plasma concentrations of glucose and insulin

Other

MeasureTime frameDescription
Inflammatory markers4 weeksPlasma concentrations of c-reactive protein and interleukin 6

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026